A Single centric, open label , observational , retrospective post market follow up Study to evaluate Safety and Performance of Sirolimus Eluting Coronary Stent System

Multimedics LLP0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

研究概览

暂无简介。

•Subjects with ischemic heart disease due to coronary artery lesion
•Subjects implanted with Sirolimus Eluting Coronary Stent from the manufacturer via Percutaneous Transluminal Coronary Angioplasty (PTCA)

•-Subjects expect in those with known allergies
•-Subjects who are indicated for coronary bypass surgery.
•-Subjects who exhibit angiographic evidence of existing thrombus.
•-Subjects allergic to L605 Chromium cobalt.
•-Subjects with a contradiction for anti-platelet / anti-coagulant therapy, this includes patients who have had major surgery, an obstetrical delivery organ biopsy, or puncture of a non- compressible vessel within 14 day of this procedure.
•-Subjects with a history of gastrointestinal bleeding, recent C.V.A., diabetic hemorrhagic retinopathy, or any condition compromised by prolonged anti-coagulant.
•-Subjects who have experienced a recent (less than 1 week) acute myocardial infarction.
•-Subjects with diffuse disease, defined as long segments of abnormal vessel without interposed normal vessel.
•-Subjects who have transplants.
•-Subjects who got implanted with any other manufacturer Sirolimus Eluting Coronary Stent System

发起方

Multimedics LLP